These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22066007)

  • 21. Liver toxicity caused by nevirapine.
    González de Requena D; Núñez M; Jiménez-Nácher I; Soriano V
    AIDS; 2002 Jan; 16(2):290-1. PubMed ID: 11807315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
    Núñez M; González-Requena D; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
    Montaner JS; Cahn P; Zala C; Casssetti LI; Losso M; Hall DB; Wruck J; McDonough M; Gigliotti M; Robinson PA;
    J Acquir Immune Defic Syndr; 2003 May; 33(1):41-6. PubMed ID: 12792354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria.
    lsa SE; Gwamzhi LN; Akolo C; Giyan J
    Niger J Med; 2010; 19(3):279-85. PubMed ID: 20845631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
    Dahri K; Ensom MH
    Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.
    Chu KM; Boulle AM; Ford N; Goemaere E; Asselman V; Van Cutsem G
    PLoS One; 2010 Feb; 5(2):e9183. PubMed ID: 20174653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
    Matteelli A; Saleri N; Villani P; Bonkoungou V; Carvalho AC; Kouanda S; Sanou MJ; Simporé J; Monno L; Carosi G; Regazzi M; Dembele M
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):64-9. PubMed ID: 19731452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
    De Maat MM; Mathôt RA; Veldkamp AI; Huitma AD; Mulder JW; Meenhorst PL; Van Gorp EC; Carlier H; Beijnen JH
    Pharmacol Res; 2002 Sep; 46(3):295-300. PubMed ID: 12220974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experience with nevirapine taken once daily in 93 HIV-infected patients].
    Allavena C; François C; Reliquet V; Perre P; Michau C; Peytavin G; Raffi F
    Pathol Biol (Paris); 1999 May; 47(5):563-5. PubMed ID: 10418041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
    Yong CL; Gathe JC; Knecht G; Orrell C; Mallolas J; Podzamczer D; Trottier B; Zhang W; Sabo JP; Vinisko R; Drulak M; Quinson AM
    HIV Clin Trials; 2017; 18(5-6):189-195. PubMed ID: 29210627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure.
    Kimulwo MJ; Okendo J; Aman RA; Ogutu BR; Kokwaro GO; Ochieng DJ; Muigai AW; Oloo FA; Ochieng W
    PLoS One; 2017; 12(2):e0172960. PubMed ID: 28235021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    van Leth F; Andrews S; Grinsztejn B; Wilkins E; Lazanas MK; Lange JM; Montaner J;
    AIDS; 2005 Mar; 19(5):463-71. PubMed ID: 15764851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
    Negredo E; Moltó J; Muñoz-Moreno JA; Pedrol E; Ribera E; Viciana P; Galindos MJ; Miralles C; Burger D; Rodriguez Fumaz C; Puig J; Gel S; Rodríguez E; Videla S; Ruiz L; Clotet B
    Antivir Ther; 2004 Jun; 9(3):335-42. PubMed ID: 15259896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?
    de Requena DG; Núñez M; Gallego O; Jiménez-Nácher I; González-Lahoz J; Soriano V
    HIV Clin Trials; 2002; 3(6):463-7. PubMed ID: 12501129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.